Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Advances in Pathogenesis and Treatment of Skin Cancer

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 25 May 2024 | Viewed by 6738

Share This Special Issue

Special Issue Editors

Dr. Enrica Flori

E-Mail Website
Guest Editor

IRCCS Istituto Dermatologico San Gallicano, 00144 Rome, Italy
Interests: skin inflammatory response; cross-talk among epidermal and dermal cells in pigmentary disorders; the role of nuclear receptors in the protective response against UV; skin cancer

Dr. Vittoria Maresca

E-Mail Website
Guest Editor

IRCCS Istituto Dermatologico San Gallicano, 00144 Rome, Italy
Interests: melanocytes; melanoma cells; alpha-MSH; MC1R; MC1R signal transduction pathways

Dr. Giorgia Cardinali

E-Mail Website
Guest Editor

San Gallicano Dermatological Institute, IRCCS, 00144 Rome, Italy
Interests: bioactive modulators of cutaneous homeostasis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Skin cancer includes various types of skin tumors, such as melanoma, basal cell and squamous cell carcinomas, cutaneous lymphomas, and other rare diseases, which have very different etiologies, incidences, therapeutic approaches, and outcomes. The incidence of skin cancers is steadily increasing, representing a significant public health concern. In recent years, significant efforts have been made to develop effective therapeutic options, although many questions remain open. We welcome research contributions focused on understanding the molecular pathways, biomarkers, oxidative stress, and skin microenvironment involved in the onset and progression of skin cancers. Exploring the mechanisms of etiopathogenesis may contribute to developing new and more effective therapeutic approaches for the prevention and treatment of skin cancer. Note that pre-clinical and clinical contributions with biomolecular approaches will also be considered.

Dr. Enrica Flori
Dr. Vittoria Maresca
Dr. Giorgia Cardinali
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

melanoma
squamous cell carcinoma
basal cell carcinoma
tumor microenvironment
epithelial–mesenchymal transition (EMT) process
ultraviolet radiation
oxidative stress
bioactive modulators
signal transduction pathways

Published Papers (5 papers)

Download All Papers

Research

Jump to: Review

15 pages, 3448 KiB

Open AccessArticle

Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells

by Ioannis Anestopoulos, Ioannis Paraskevaidis, Sotiris Kyriakou, Lambrini E. Giova, Dimitrios T. Trafalis, Sotiris Botaitis, Rodrigo Franco, Aglaia Pappa and Mihalis I. Panayiotidis

Int. J. Mol. Sci. 2024, 25(5), 2745; https://doi.org/10.3390/ijms25052745 - 27 Feb 2024

Viewed by 857

Abstract

In this study, we utilized an in vitro model consisting of human malignant melanoma as well as non-tumorigenic immortalized keratinocyte cells with the aim of characterizing the therapeutic effectiveness of the clinical epigenetic drug Tazemetostat alone or in combination with various isothiocyanates. In doing so, we assessed markers of cell viability, apoptotic induction, and expression levels of key proteins capable of mediating the therapeutic response. Our data indicated, for the first time, that Tazemetostat caused a significant decrease in viability levels of malignant melanoma cells in a dose- and time-dependent manner via the induction of apoptosis, while non-malignant keratinocytes were more resistant. Moreover, combinatorial treatment protocols caused a further decrease in cell viability, together with higher apoptotic rates. In addition, a significant reduction in the Polycomb Repressive Complex 2 (PRC2) members [e.g., Enhancer of Zeste Homologue 2 (EZH2), Embryonic Ectoderm Development (EED), and suppressor of zeste 12 (SUZ12)] and tri-methylating lysine 27 at Histone 3 (H3K27me3) protein expression levels was observed, at least partially, under specific combinatorial exposure conditions. Reactivation of major apoptotic gene targets was determined at much higher levels in combinatorial treatment protocols than Tazemetostat alone, known to be involved in the induction of intrinsic and extrinsic apoptosis. Overall, we developed an optimized experimental therapeutic platform aiming to ensure the therapeutic effectiveness of Tazemetostat in malignant melanoma while at the same time minimizing toxicity against neighboring non-tumorigenic keratinocyte cells. Full article

(This article belongs to the Special Issue Advances in Pathogenesis and Treatment of Skin Cancer)

► Show Figures

Figure 1

13 pages, 1494 KiB

Open AccessArticle

VEGFC Gene Expression Is Associated with Tumor Progression and Disease-Free Survival in Cutaneous Squamous Cell Carcinoma

by Omar García-Pérez, Leticia Melgar-Vilaplana, Inés Sifaoui, Aleksandra Śmietańska, Elizabeth Córdoba-Lanús and Ricardo Fernández-de-Misa

Int. J. Mol. Sci. 2024, 25(1), 379; https://doi.org/10.3390/ijms25010379 - 27 Dec 2023

Viewed by 755

Abstract

Cutaneous squamous cell carcinoma (CSCC) is one of the most common cancers in the skin. CSCC belongs to the non-melanoma skin cancers, and its incidence is increasing every year around the world. The principal routes of tumor progression are related to angiogenesis and lymphangiogenesis. In this study, we assess the gene expression of the relevant biomarkers of both routes in 49 formalin-fixed paraffin-embedded (FFPE) CSCC samples in an attempt to determine a molecular profile that correlates with the tumor progression and disease-free survival (DFS). The results were enhanced by a posttranscriptional analysis using an immunofluorescence assay. Overexpression of the vascular endothelial growth factor C (VEGFC) gene was found in patients with tumor progression (p = 0.022) and in patients with perineural invasion (p = 0.030). An increased expression of protein VEGFC in samples with tumor progression supported these results (p = 0.050). In addition, DFS curves showed differences (p = 0.027) for tumors with absent-low VEGFC expression versus those with high levels of VEGFC expression. No significant influence on DFS was detected for the remaining analyzed genes. VEGFC expression was found to be a risk factor in the disease progression (HR = 2.675; 95% CI: 1.089–6.570; p = 0.032). Our main results suggest that VEGFC gene expression is closely related to tumor progression, DFS, and the presence of perineural invasion. Full article

(This article belongs to the Special Issue Advances in Pathogenesis and Treatment of Skin Cancer)

► Show Figures

Figure 1

17 pages, 2751 KiB

Open AccessArticle

A Side-by-Side Comparison of Wildtype and Variant Melanocortin 1 Receptor Signaling with Emphasis on Protection against Oxidative Damage to DNA

by Sonia Cerdido, José Sánchez-Beltrán, Ana Lambertos, Marta Abrisqueta, Lidia Padilla, Cecilia Herraiz, Conchi Olivares, Celia Jiménez-Cervantes and José C. García-Borrón

Int. J. Mol. Sci. 2023, 24(18), 14381; https://doi.org/10.3390/ijms241814381 - 21 Sep 2023

Cited by 2 | Viewed by 973

Abstract

Common variants of the MC1R gene coding the α-melanocyte stimulating hormone receptor are associated with light skin, poor tanning, blond or red hair, and increased melanoma risk, due to pigment-dependent and -independent effects. This complex phenotype is usually attributed to impaired activation of cAMP signaling. However, several MC1R variants show significant residual coupling to cAMP and efficiently activate mitogenic extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling. Yet, residual signaling and the key actions of wildtype and variant MC1R have never been assessed under strictly comparable conditions in melanocytic cells of identical genetic background. We devised a strategy based on CRISPR-Cas9 knockout of endogenous MC1R in a human melanoma cell line wildtype for BRAF, NRAS and NF1, followed by reconstitution with epitope-labeled MC1R constructs, and functional analysis of clones expressing comparable levels of wildtype, R151C or D294H MC1R. The proliferation rate, shape, adhesion, motility and sensitivity to oxidative DNA damage were compared. The R151C and D294H RHC variants displayed impaired cAMP signaling, intracellular stability similar to the wildtype, triggered ERK1/2 activation as effectively as the wildtype, and afforded partial protection against oxidative DNA damage, although less efficiently than the wildtype. Therefore, common melanoma-associated MC1R variants display biased signaling and significant genoprotective activity. Full article

(This article belongs to the Special Issue Advances in Pathogenesis and Treatment of Skin Cancer)

► Show Figures

Figure 1

17 pages, 2763 KiB

Open AccessArticle

Role of Rho/MRTF in Aggressive Vemurafenib-Resistant Murine Melanomas and Immune Checkpoint Upregulation

by Bardees M. Foda and Richard R. Neubig

Int. J. Mol. Sci. 2023, 24(18), 13785; https://doi.org/10.3390/ijms241813785 - 7 Sep 2023

Viewed by 1127

Abstract

Cutaneous melanoma is the deadliest skin cancer. Most have Ras-MAPK pathway (BRAF^V600E or NRAS) mutations and highly effective targeted therapies exist; however, they and immune therapies are limited by resistance, in part driven by small GTPase (Rho and Rac) activation. To facilitate preclinical studies of combination therapies to provide durable responses, we describe the first mouse melanoma lines resistant to BRAF inhibitors. Treatment of mouse lines, YUMM1.7 and YUMMER, with vemurafenib (Vem), the BRAF^V600E-selective inhibitor, resulted in high-level resistance (IC₅₀ shifts 20–30-fold). Resistant cells showed enhanced activation of Rho and the downstream transcriptional coactivator, myocardin-related transcription factor (MRTF). Resistant cells exhibited increased stress fibers, nuclear translocation of MRTF-A, and an increased MRTF-A gene signature. Pharmacological inhibition of the Rho/MRTF pathway using CCG-257081 reduced viability of resistant lines and enhanced sensitivity to Vem. Remarkably, co-treatment of parental lines with Vem and CCG-257081 eliminated resistant colony development. Resistant cells grew more slowly in vitro, but they developed highly aggressive tumors with a shortened survival of tumor-bearing mice. Increased expression of immune checkpoint inhibitor proteins (ICIs) in resistant lines may contribute to aggressive in vivo behavior. Here, we introduce the first drug-resistant mouse melanoma models for assessing combinations of targeted and immune therapies. Full article

(This article belongs to the Special Issue Advances in Pathogenesis and Treatment of Skin Cancer)

► Show Figures

Figure 1

Review

Jump to: Research

17 pages, 722 KiB

Open AccessReview

Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management

by Laura Maria Gosman, Dana-Antonia Țăpoi and Mariana Costache

Int. J. Mol. Sci. 2023, 24(21), 15881; https://doi.org/10.3390/ijms242115881 - 1 Nov 2023

Cited by 4 | Viewed by 2270

Abstract

Cutaneous melanoma (CM) is an increasingly significant public health concern. Due to alarming mortality rates and escalating incidence, it is crucial to understand its etiology and identify emerging biomarkers for improved diagnosis and treatment strategies. This review aims to provide a comprehensive overview of the multifactorial etiology of CM, underscore the importance of early detection, discuss the molecular mechanisms behind melanoma development and progression, and shed light on the role of the potential biomarkers in diagnosis and treatment. The pathogenesis of CM involves a complex interplay of genetic predispositions and environmental exposures, ultraviolet radiation exposure being the predominant environmental risk factor. The emergence of new biomarkers, such as novel immunohistochemical markers, gene mutation analysis, microRNA, and exosome protein expressions, holds promise for improved early detection, and prognostic and personalized therapeutic strategies. Full article

(This article belongs to the Special Issue Advances in Pathogenesis and Treatment of Skin Cancer)

► Show Figures